1. Home
  2. ADNT vs HRMY Comparison

ADNT vs HRMY Comparison

Compare ADNT & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADNT
  • HRMY
  • Stock Information
  • Founded
  • ADNT 2016
  • HRMY 2017
  • Country
  • ADNT Ireland
  • HRMY United States
  • Employees
  • ADNT N/A
  • HRMY N/A
  • Industry
  • ADNT Auto Parts:O.E.M.
  • HRMY Biotechnology: Pharmaceutical Preparations
  • Sector
  • ADNT Consumer Discretionary
  • HRMY Health Care
  • Exchange
  • ADNT Nasdaq
  • HRMY Nasdaq
  • Market Cap
  • ADNT 1.3B
  • HRMY 2.0B
  • IPO Year
  • ADNT N/A
  • HRMY 2020
  • Fundamental
  • Price
  • ADNT $22.18
  • HRMY $32.11
  • Analyst Decision
  • ADNT Hold
  • HRMY Strong Buy
  • Analyst Count
  • ADNT 9
  • HRMY 9
  • Target Price
  • ADNT $17.31
  • HRMY $54.22
  • AVG Volume (30 Days)
  • ADNT 1.5M
  • HRMY 624.9K
  • Earning Date
  • ADNT 08-05-2025
  • HRMY 08-05-2025
  • Dividend Yield
  • ADNT N/A
  • HRMY N/A
  • EPS Growth
  • ADNT N/A
  • HRMY 13.13
  • EPS
  • ADNT N/A
  • HRMY 2.62
  • Revenue
  • ADNT $14,384,000,000.00
  • HRMY $744,852,000.00
  • Revenue This Year
  • ADNT N/A
  • HRMY $20.10
  • Revenue Next Year
  • ADNT N/A
  • HRMY $18.01
  • P/E Ratio
  • ADNT N/A
  • HRMY $12.25
  • Revenue Growth
  • ADNT N/A
  • HRMY 20.62
  • 52 Week Low
  • ADNT $10.04
  • HRMY $26.47
  • 52 Week High
  • ADNT $26.59
  • HRMY $41.61
  • Technical
  • Relative Strength Index (RSI)
  • ADNT 82.50
  • HRMY 42.69
  • Support Level
  • ADNT $19.31
  • HRMY $31.25
  • Resistance Level
  • ADNT $19.91
  • HRMY $33.69
  • Average True Range (ATR)
  • ADNT 0.70
  • HRMY 1.03
  • MACD
  • ADNT 0.17
  • HRMY -0.15
  • Stochastic Oscillator
  • ADNT 93.90
  • HRMY 20.90

About ADNT Adient plc

Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.8 billion in fiscal 2024 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2024 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.7 billion but will likely be below $14 billion in fiscal 2025 on tariff interruptions and divesting some lower-quality business.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: